全文获取类型
收费全文 | 4017篇 |
免费 | 239篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 142篇 |
妇产科学 | 232篇 |
基础医学 | 443篇 |
口腔科学 | 77篇 |
临床医学 | 284篇 |
内科学 | 918篇 |
皮肤病学 | 76篇 |
神经病学 | 156篇 |
特种医学 | 118篇 |
外科学 | 532篇 |
综合类 | 118篇 |
一般理论 | 4篇 |
预防医学 | 146篇 |
眼科学 | 375篇 |
药学 | 347篇 |
中国医学 | 14篇 |
肿瘤学 | 252篇 |
出版年
2024年 | 3篇 |
2023年 | 36篇 |
2022年 | 94篇 |
2021年 | 203篇 |
2020年 | 118篇 |
2019年 | 131篇 |
2018年 | 169篇 |
2017年 | 92篇 |
2016年 | 146篇 |
2015年 | 142篇 |
2014年 | 195篇 |
2013年 | 221篇 |
2012年 | 389篇 |
2011年 | 383篇 |
2010年 | 178篇 |
2009年 | 119篇 |
2008年 | 220篇 |
2007年 | 217篇 |
2006年 | 202篇 |
2005年 | 180篇 |
2004年 | 154篇 |
2003年 | 133篇 |
2002年 | 90篇 |
2001年 | 53篇 |
2000年 | 66篇 |
1999年 | 46篇 |
1998年 | 22篇 |
1997年 | 21篇 |
1996年 | 17篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 19篇 |
1992年 | 21篇 |
1991年 | 18篇 |
1990年 | 18篇 |
1989年 | 24篇 |
1988年 | 19篇 |
1987年 | 9篇 |
1986年 | 17篇 |
1985年 | 8篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1981年 | 5篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 5篇 |
1970年 | 4篇 |
1969年 | 4篇 |
1968年 | 2篇 |
1967年 | 3篇 |
排序方式: 共有4267条查询结果,搜索用时 796 毫秒
161.
162.
Gaurav Gupta Idris Yakubu Chandra S. Bhati Yiran Zhang Le Kang Julie A. Patterson Ayana Andrews‐Joseph Anam Alam Andrea Ferreira‐Gonzalez Dhiren Kumar Irfan K. Moinuddin Layla Kamal Anne L. King Marlon Levy Amit Sharma Adrian Cotterell Trevor W. Reichman Aamir Khan Pamela Kimball Rodney Stiltner Mary Baldecchi Nathaniel Brigle Todd Gehr Richard K. Sterling 《American journal of transplantation》2020,20(3):739-751
We conducted an adaptive design single‐center pilot trial between October 2017 and November 2018 to determine the safety and efficacy of ultra‐short‐term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)‐nucleic acid test (NAT) positive donors to HCV negative kidney recipients (D+/R?). In Group 1, 10 patients received one dose of SOF/VEL (sofusbuvir/velpatasvir) pretransplant and one dose on posttransplant Day 1. In Group 2A (N = 15) and the posttrial validation (Group 2B; N = 25) phase, patients received two additional SOF/VEL doses (total 4) on Days 2 and 3 posttransplant. Development of posttransplant HCV transmission triggered 12‐week DAA therapy. For available donor samples (N = 27), median donor viral load was 1.37E + 06 IU/mL (genotype [GT]1a: 70%; GT2: 7%; GT3: 23%). Overall viral transmission rate was 12% (6/50; Group 1:30% [3/10]; Group 2A:13% [2/15]; Group 2B:4% [1/25]). For the 6 viremic patients, 5 (83%) achieved sustained virologic response (3 with first‐line DAA therapy; and two after retreatment with second‐line DAA). At a median follow‐up of 8 months posttransplant, overall patient and allograft survivals were 98%, respectively. The 4‐day strategy reduced viral transmission to 7.5% (3/40; 95% confidence interval [CI]: 1.8%‐20.5%) and could result in avoidance of prolonged posttransplant DAA therapy for most D+/R ? transplants. 相似文献
163.
164.
P. G. Paul Talwar Prathap Harneet Kaur Khan Shabnam Dimple Kandhari Gaurav Chopade 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2014,18(3)
Background and Objectives:
The purpose of this study is to estimate the cumulative incidence, patient characteristics, and potential risk factors for secondary hemorrhage after total laparoscopic hysterectomy.Methods:
All women who underwent total laparoscopic hysterectomy at Paul''s Hospital between January 2004 and April 2012 were included in the study. Patients who had bleeding per vaginam between 24 hours and 6 weeks after primary surgery were included in the analysis.Results:
A total of 1613 patients underwent total laparoscopic hysterectomy during the study period, and 21 patients had secondary hemorrhage after hysterectomy. The overall cumulative incidence of secondary hemorrhage after total laparoscopic hysterectomy was 1.3%. The mean size of the uterus was 541.4 g in the secondary hemorrhage group and 318.9 g in patients without hemorrhage, which was statistically significant. The median time interval between hysterectomy and secondary hemorrhage was 13 days. Packing was sufficient to control the bleeding in 13 patients, and 6 patients required vault suturing. Laparoscopic coagulation of the uterine artery was performed in 1 patient. Uterine artery embolization was performed twice in 1 patient to control the bleeding.Conclusions:
Our data suggest that secondary hemorrhage is rare but may occur more often after total laparoscopic hysterectomy than after other hysterectomy approaches. Whether it is related to the application of thermal energy to tissues, which causes more tissue necrosis and devascularization than sharp culdotomy in abdominal and vaginal hysterectomies, is not clear. A large uterus size, excessive use of an energy source for the uterine artery, and culdotomy may play a role. 相似文献165.
166.
167.
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lin B Catley L LeBlanc R Mitsiades C Burger R Tai YT Podar K Wartmann M Chauhan D Griffin JD Anderson KC 《Blood》2005,105(1):350-357
In this study, we investigated the in vitro and in vivo efficacy of patupilone (epothilone B, EPO906), a novel nontaxane microtubule stabilizing agent, in treatment of multiple myeloma (MM). Patupilone directly inhibited growth and survival of MM cells, including those resistant to conventional chemotherapies, such as the taxane paclitaxel. Patupilone induced G2M arrest of MM cells, with subsequent apoptosis. Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1), 2 known growth and survival factors for MM, did not protect MM.1S cells against patupilone-induced cell death. Proliferation of MM cells induced by adherence to bone marrow stromal cells (BMSCs) was also inhibited by patupilone and was paralleled by down-regulation of vascular endothelial growth factor (VEGF) secretion. Importantly, stimulation of cells from patients with MM, either with IL-6 or by adherence to BMSCs, enhanced the anti-proliferative and proapoptotic effects of patupilone. Moreover, patupilone was effective against MM cell lines that overexpress the MDR1/P-glycoprotein multidrug efflux pump. In addition, patupilone was effective in slowing tumor growth and prolonging median survival of mice that received orthotopical transplants with MM tumor cells. Taken together, these preclinical findings suggest that patupilone may be a safe and effective drug in the treatment of MM, providing the framework for clinical studies to improve patient outcome in MM. 相似文献
168.
Raje N Hideshima T Davies FE Chauhan D Treon SP Young G Tai YT Avigan D Gong J Schlossman RL Richardson P Kufe DW Anderson KC 《British journal of haematology》2004,125(3):343-352
Multiple myeloma (MM) cells express certain tumour-associated antigens (TAAs) that could serve as targets for active-specific immunotherapy. The aim of the present study was to test the MM/dendritic cell (DC) fusion as a vaccination strategy. We fused MM cells with DC to generate fusion cells (FCs) and tested their antigen presenting cell (APC) function in mixed lymphocyte reactions and cytotoxicity assays. First, the HS Sultan and SK0-007 HAT sensitive human MM cell lines and DCs generated from peripheral blood of normal donors were fused in the presence of 50% polyethylene glycol to form FCs. Next, tumour cells freshly isolated from patients were similarly fused with autologous DCs to generate FCs. The FCs demonstrated a biphenotypic profile, confirmed both by flow-cytometry and dual immunofluorescence microscopy. These FCs induced MM-specific cytotoxicity. FCs, but not MM cells or DCs alone, were potent stimulators of autologous patient T cells. More importantly, FC-primed autologous peripheral blood mononuclear cells demonstrated major histocompatibility complex-restricted MM-specific cytolysis. These studies therefore demonstrated that MM/DC FC can trigger an autologous immune response to MM cells and formed the framework for a clinical trial currently underway. 相似文献
169.
Interleukin-6 Inhibits Fas-Induced Apoptosis and Stress-Activated Protein Kinase Activation in Multiple Myeloma Cells 总被引:10,自引:20,他引:10
170.
Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis 总被引:5,自引:0,他引:5
Low JM Chauhan AK Kietz DA Daud U Pepmueller PH Moore TL 《The Journal of rheumatology》2004,31(9):1829-1833
OBJECTIVE: Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been found in sera of 76% of patients with rheumatoid arthritis (RA), mainly in rheumatoid factor (RF) positive patients, with a specificity of 96%. We evaluated the presence of anti-CCP antibodies in patients with juvenile idiopathic arthritis (JIA) and assessed the possibility of synthetic citrullinated peptides as antigenic determinants in JIA. METHODS: The presence of anti-CCP antibodies was determined using 3 synthetic citrullinated peptide variants and 2 commercial kits (Inova Diagnostics and Axis-Shield Diagnostics) optimized for detecting JIA-specific antibodies in serum by an ELISA based assay. We evaluated 66 patients with JIA (16 RF positive polyarthritis, 18 RF negative polyarthritis, 19 oligoarthritis, and 13 systemic arthritis). We also tested 9 adult RA patients, 34 patients with systemic lupus erythematosus (SLE), and 25 healthy persons as controls. RESULTS: Significant concentrations of anti-CCP antibodies were detected in the majority of RF positive JIA patients with polyarthritis. Using the 2 synthetic linear peptides, 12/16 (75%) were positive; 9/12 (75%) were positive with the Inova kit and 9/10 (90%) were positive with the Axis-Shield kit. However, utilizing the synthetic linear peptides, significant concentrations of anti-CCP antibodies were detected in 51/66 (77%) JIA patients, including 15/18 (83%) RF negative polyarthritis, 16/19 (84%) oligoarthritis, and 8/13 (62%) systemic arthritis patients. No healthy control showed elevated antibody levels. In contrast, 4/9 (44%) patients with adult RA and 2/6 (33%) with SLE had elevated anti-CCP levels. The synthetic cyclic variant cfc-1-cyc yielded significant anti-CCP levels for 13/14 (93%) patients with RF negative polyarthritis, 6/10 (60%) with oligoarthritis, and 3/7 (43%) with systemic arthritis, and 8/9 (88%) RF positive patients. No healthy control had increased anti-CCP levels. However, 4/9 (44%) adult RA and 9/34 (26%) SLE patients were found to have elevated anti-CCP levels. Using the Inova and Axis-Shield kits, much smaller percentages were found in the RF negative patients, with only 4/16 (25%) in the oligoarthritis and RF negative polyarthritis patients with the Inova kits and 0/25 (0%) by the Axis-Shield kits. The Inova kit revealed elevated anti-CCP antibodies in 5/9 (56%) adult RA patients and in 8/34 (24%) SLE patients. No healthy control had elevated anti-CCP antibodies. However, the Axis-Shield kits did not detect anti-CCP antibodies in adult RA (0/9) or SLE (0/34) patients. Moreover, 0/25 (0%) healthy individuals exhibited anti-CCP levels. The presence of anti-CCP antibodies correlated more frequently with the presence of RF. CONCLUSION: This study confirms the presence of anti-CCP antibodies in patients with JIA, especially those with RF positive polyarthritis, by all ELISA based methods. Use of synthetic peptides also revealed anti-CCP antibodies in a percentage of RF negative patients with polyarthritis, oligoarthritis, and systemic arthritis; there was a loss in specificity, but an increase in sensitivity. These results suggest that antibodies to these antigenic peptides may be markers for JIA, and indicate a possible role of citrulline-containing epitopes in the pathogenesis of JIA. 相似文献